@article{ccc0ccde712f4f66bc2e180755c329e1,
title = "Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People with Treated Human Immunodeficiency Virus",
abstract = "Background. Inflammasome activation is increased in people with human immunodeficiency virus (PWH), but its relationship with coronary plaque is poorly understood in this setting. Methods. In a large human immunodeficiency virus cardiovascular prevention cohort, relationships between caspase-1, interleukin (IL)-1β, and IL-18 and coronary plaque indices were assessed by multivariate logistic regression. Results. Higher IL-18 and IL-1β were associated with Leaman score, an integrative measure of plaque burden and composition. Conclusions. As Leaman score >5 is associated with cardiovascular events in the general population, future work is needed to determine how the inflammasome relates to events and whether strategies to reduce its activation affect events or plaque progression among PWH.",
keywords = "HIV, Leaman score, atherosclerosis, inflammasome",
author = "Schnittman, {Samuel R.} and Kitch, {Douglas W.} and Swartz, {Talia H.} and Burdo, {Tricia H.} and Fitch, {Kathleen V.} and Sara McCallum and Flynn, {Jacqueline M.} and Fulda, {Evelynne S.} and Diggs, {Marissa R.} and Stapleton, {Jack T.} and Casado, {Jos{\'e} L.} and Jana Taron and Currier, {Judith S.} and Zanni, {Markella V.} and Carlos Malvestutto and Fichtenbaum, {Carl J.} and Aberg, {Judith A.} and Ribaudo, {Heather J.} and Lu, {Michael T.} and Douglas, {Pamela S.} and Grinspoon, {Steven K.}",
note = "Funding Information: We thank the study participants, site staff, and study-associated personnel for their ongoing contributions to the trial. In addition, we thank the AIDS Clinical Trials Group (ACTG) for clinical site support; the ACTG Clinical Trials Specialists (Laura Moran and Jhoanna Roa) for regulatory support; the data management center, Frontier Science Foundation, for data support; and the Center for Biostatistics in AIDS Research for statistical support. This work was supported through National Institutes of Health (NIH), National Institute of Heart, Lung, and Blood Institute (NHLBI) Grants U01HL123336, to the REPRIEVE Clinical Coordinating Center, and U01HL123339, to the REPRIEVE Data Coordinating Center, as well as through funding from Kowa Pharmaceuticals America Inc., Gilead Sciences, and ViiV Healthcare. National Institute of Allergy and Infectious Diseases (NIAID) has supported this study through Grants UM1 AI068636, which supports the AIDS Clinical Trials Group (ACTG) Leadership and Operations Center, and UM1 AI106701, which supports the ACTG Laboratory. SRS was supported through NIAID by T32 AI007387. THS was supported through National Institute on Drug Abuse by R01 DA052255 and NIAID by R21 AI152833. THB was supported in part through NHLBI by R01 HL141132. MVZ was supported in part through NIAID by K24 AI57882. SKG was supported in part through National Institute of Diabetes and Digestive and Kidney Diseases by P30 DK40561. Funding Information: Potential conflicts of interest. SRS reports grant support through his institution from NIH/NIAID. THS reports grant support through her institution from NIH/NIAID and NIH/National Institute of Allergy and Infectious Diseases outside the submitted work. THB reports equity in Excision BioTherapeutics and serves on their Scientific Advisory Board, outside the submitted work. JTS reports grant support through his institution from NIH/NIAID, the US Department of Veterans Affairs, HRSA (Ryan White HIV/AIDS Program), and Abbvie, DSMB service for Transposon Therapeutics, Inc., and honoraria for lectures at Iowa State University, all outside the submitted work. JLC reports honoraria for presentations for Gilead, MSD, and Janssen and advisory board membership for ViiV Healthcare and Gilead Sciences, all outside the submitted work. JT reports funding by Deutsche Forschungsgesellschaft ([DFG], German Research Foundation), speakers bureau for Siemens Healthcare GmbH and Bayer AG, reviewer for Universimed Cross Media Content GmbH, and consultant for Core Lab Black Forrest GmbH, all outside the submitted work. JSC reports consulting fees from Merck, outside the submitted work. MVZ reports grant support through her institution from NIH/NIAID and Gilead Sciences, Inc. relevant to the conduct of the study, as well as grants from NIH/NIAID and NIH/National Heart, Lung, and Blood Institute (NHLBI) outside the submitted work. CM reports institutional research support by Lilly and honoraria from ViiV Healthcare and Gilead Sciences for advisory board membership, all outside the submitted work. CJF reports grant support through his institution from Gilead Sciences, ViiV Healthcare, GSK, Janssen, Abbvie, Merck, Amgen, and Cytodyn; personal fees from Theratechnologies and ViiV for consulting and participation on Advisory Board unrelated to REPRIEVE; and DSMB Chair for Intrepid Study, all outside the submitted work. JAA reports institutional research support for clinical trials from Atea, Emergent Biosolutions, Frontier Technologies, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Pfizer, Regeneron, and ViiV Healthcare and personal fees for advisory boards from GlaxoSmithKline/ViiV and Merck; and participation on DSMB for Kintor Pharmaceuticals, all outside the submitted work. HJR reports grants from NIH/NHLBI and Kowa Pharmaceuticals during the conduct of the study, as well as grants from NIH/NIAID, NIH/NHLBI, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, and NIH/National Institute on Aging, outside the submitted work. MTL reports grant support through his institution from Kowa Pharmaceuticals America, Inc., for the conduct of the study. He also reports grant support from MedImmune/AstraZeneca and personal fees from PQBypass, outside of the current work. SKG reports grant support through his institution from NIH, Kowa Pharmaceuticals America, Inc., Gilead Sciences, Inc., and ViiV Healthcare for the conduct of the study; personal fees from Theratechnologies and ViiV; and service on the Scientific Advisory Board of Marathon Asset Management, all outside the submitted work. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",
year = "2023",
month = mar,
day = "1",
doi = "10.1093/ofid/ofad106",
language = "English",
volume = "10",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "3",
}